APP and neoplasm: We have previously demonstrated that APP-coated p53 variant-expressing oncolytic Ad (oAd-vp53/APP) exerted synergistic antitumor effect against both CAR-positive and -negative breast cancer xenografts via either intratumoral or systemic administration due to enhanced accumulation of both PTX and oncolytic Ad in tumor tissues (32).